Systematic review of biologic therapy safety in pregnant and breastfeeding psoriasis patients
10.11855/j.issn.0577-7402.0911.2025.0219
- VernacularTitle:妊娠及哺乳期银屑病患者生物制剂治疗安全性的系统评价
- Author:
Zong-Yang LI
1
;
Zheng GU
;
Hui-Jing WANG
;
Yu-Shi FANG
;
Zi LI
;
Xiao-Yan ZHANG
Author Information
1. 北京中医药大学研究生院,北京 100029;中日友好医院皮肤科,北京 100029
- Keywords:
psoriasis;
pregnancy;
lactation;
biological agents;
safety
- From:
Medical Journal of Chinese People's Liberation Army
2025;50(5):545-552
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically review and quantitatively analyze the safety of biologic agents for the clinical treatment of psoriasis during pregnancy and lactation.Methods The literature from start of database to June 27,2023,was searched in MEDLINE(PubMed),Embase,Cochrane Library,and Web of Science by two researcher.Quality of included studies was assessed by the quality evaluation tool of case series from Australian JBI Evidence Based Healthcare Centre.According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses(PRISMA),a systematic review and was conducted to assess pregnancy or breastfeeding outcomes in psoriasis patients exposed to biologics within 3 months prior to pregnancy,during pregnancy or breastfeeding.Data on pregnancy and exposure characteristics were pooled,and the prevalence of adverse pregnancy outcome was summarized using a random effects model.Results A total of 54 studies involving 1206 pregnancies in 1177 female patients with psoriasis exposed to biologic agents were included in the analysis.Systematic review results demonstrated that the majority of the exposures were limited to early pregnancy,with pooled spontaneous abortion rates,elective abortion rates,overall mortality,preterm birth rates,incidence of low birth weights,and congenital anomalies similar to those of general population(P>0.05).Furthermore,no serious adverse reactions were reported during lactation.Conclusions The use of biologic agents in pregnant and breastfeeding women with psoriasis does not significantly increase the risk of adverse pregnancy outcomes and does not affect neonatal health or growth.However,the limited available safety data underscores the necessity of further studies to establish the relationship between psoriasis,biologic agents,and pregnancy/lactation outcomes,thereby providing comprehensive guidance for clinical practice.
